Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT00993109

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT00993109
Other papers using this trial's data
  • Improved blood pressure control with nifedipine GITS/valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia: results from the ADVISE study, a randomized trial Cardiovascular therapeutics, 2012-12 DOI, PubMed 23134522

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT00993109. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2011-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension
Condition
Hypertension
Intervention (Drug)
Adalat (Nifedipine, BAYA1040)
Intervention (Drug)
Diovan (Valsartan)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct00993109
Content hash
83301d16a3d1d1fbf69cc99a4202c54381792cefeff76a0a6d0c8891a0aded2e